Quantcast

Latest Thiazoles Stories

2010-10-21 07:00:00

TAMPA, Fla., Oct. 21 /PRNewswire/ -- Romark Laboratories, L.C. and Intercell AG (VSE; "ICLL") today announced plans to commence clinical trials of Romark's antiviral drug, nitazoxanide, in combination with Intercell's investigational therapeutic hepatitis C virus (HCV) vaccine, IC41, during the first half of 2011. (Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20100201/FL47022LOGO ) Intercell's vaccine candidate has demonstrated...

2010-05-04 14:45:00

TAMPA, Fla., May 4 /PRNewswire/ -- Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented this afternoon as an oral communication at a late breaking forum of the American Gastroenterological Association Institute (AGA Institute) during Digestive Disease Week 2010 in New Orleans, Louisiana. (Logo:...

2010-04-15 09:27:00

TAMPA, Fla., April 15 /PRNewswire/ -- Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented as a late breaking communication at the International Liver Congress(TM) 2010, the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria. (Logo:...

2010-04-01 13:30:00

NORTHBROOK, Ill. and REINACH, Switzerland, April 1 /PRNewswire/ -- Horizon Therapeutics, Inc. and Nitec Pharma AG, both privately held companies, today announced a definitive agreement in which the two companies have combined in an all-stock transaction. The combined company also completed a concurrent preferred stock financing in conjunction with the transaction. The combined company will be named Horizon Pharma, Inc., and will be led by Timothy P. Walbert, previously president and...

2010-02-01 09:50:00

TAMPA, Fla., Feb. 1 /PRNewswire/ -- Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of Alinia® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain. (Logo: http://www.newscom.com/cgi-bin/prnh/20100201/FL47022 ) The clinical trial is being conducted in approximately 25 sites across the United States and is expected to enroll 440 adult patients with...

2009-12-01 08:00:00

SCHAUMBURG, Ill., Dec. 1 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the launch of two antibiotics: cefoxitin for injection, USP and ceftriaxone for injection, USP. Both are antibiotics of the cephalosporin family and have activity against gram-positive and gram-negative bacteria. Sagent will launch ceftriaxone in a 10 g vial in December to complement the four vial sizes launched by Sagent in July 2008. Cefoxitin 1 g and...

8d1852f2755268034d663d20090754771
2009-07-14 09:10:00

Wild birds of several species are dying in large numbers from a paralytic disease with hitherto unknown cause in the Baltic Sea area. A research team at Stockholm University, Sweden, led by Associate Professor Lennart Balk, has demonstrated strong relationships between this disease, breeding failure, and advanced thiamine (vitamin B1) deficiency in eggs, young, and adults. The results are presented in the article "Wild birds of declining European species are dying from a thiamine deficiency...

2009-03-02 06:00:00

Editorial Accompanies Manuscript in March Issue TAMPA, Fla., March 2 /PRNewswire/ -- A study evaluating nitazoxanide in combination with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV) infection with genotype 4 was published in the March issue of Gastroenterology, the official journal of the American Gastroenterological Association Institute (AGA Institute). The study showed that the addition of nitazoxanide to standard-of-care therapy increased the rate...

2009-02-17 15:30:00

Chugai Pharmaceutical Gains Rights to Develop and Market Nitazoxanide for the Treatment of Chronic Hepatitis C TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical Co. Ltd., a member of the Roche Group, today announced that the two companies have entered into an exclusive license agreement for the development and commercialization of nitazoxanide as a treatment of chronic hepatitis C in Japan. Under the terms of the...

2009-02-17 06:00:00

Studies presented at the 19th Conference of the Asian Pacific Association for the Study of the Liver (APASL) Demonstrated Favorable Pharmacokinetics and Significant Reduction in Viral Load TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced results from international Phase I and II clinical trials evaluating a controlled release version of nitazoxanide in the treatment of chronic hepatitis C virus (HCV) infection. In the phase...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.